Form 8-K - Current report:
SEC Accession No. 0001193125-24-248678
Filing Date
2024-10-31
Accepted
2024-10-31 16:12:54
Documents
16
Period of Report
2024-10-31
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d904494d8k.htm   iXBRL 8-K 29405
2 EX-5.1 d904494dex51.htm EX-5.1 13036
3 EX-10.1 d904494dex101.htm EX-10.1 13365
7 GRAPHIC g904494img01.jpg GRAPHIC 20159
  Complete submission text file 0001193125-24-248678.txt   216527

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA nrix-20241031.xsd EX-101.SCH 2852
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE nrix-20241031_lab.xml EX-101.LAB 17996
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nrix-20241031_pre.xml EX-101.PRE 11263
18 EXTRACTED XBRL INSTANCE DOCUMENT d904494d8k_htm.xml XML 3642
Mailing Address 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158
Business Address 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158 (415) 660-5320
Nurix Therapeutics, Inc. (Filer) CIK: 0001549595 (see all company filings)

EIN.: 270838048 | State of Incorp.: DE | Fiscal Year End: 1130
Type: 8-K | Act: 34 | File No.: 001-39398 | Film No.: 241415359
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)